|Title:|| Treatment of HTLV-I infections|
|Abstract:||Treatment of animals or humans carrying or infected with HTLV-I, HTLV-I (including HTLV-I-associated leukemias or lymphomas), non-A, non-B hepatitis virus, hepatitis B virus, EBV, equine infectious anaemia or other lentiviruses or having antibodies to said viruses is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.|
|Inventor(s):|| Rideout; Janet Litster (Raleigh, NC), Barry; David Walter (Chapel Hill, NC), Lehrman; Sandra Nusinoff (Durham, NC), St. Clair; Martha Heider (Durham, NC), Furman; Phillip Allen (Durham, NC) |
|Assignee:|| Glaxo Wellcome Inc. (Research Triangle Park, NC) |
|Filing Date:||Jun 26, 1997|
|Claims:||1. A method of treating a human infected with HTLV-I comprising administering to said human an effective treatment amount of 3'-azido-3'-deoxythymidine, or a pharmaceutically acceptable salt thereof, or the 5'-mono-, di- or triphosphate thereof or a pharmaceutically acceptable salt of said phosphate, in combination with an interferon. |
2. The method of claim 1 wherein the interferon is .alpha.-interferon.